Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck To Revisit M&A Strategy Under CEO Clark; Is A Merger In The Mix?

  • News

Executive Summary

Merck will revisit its merger and acquisition strategy under newly appointed CEO Richard Clark, with all options - including a large-scale merger - on the table

You may also be interested in...



Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire

Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level

Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire

Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level

Merck Drops Strict “No Merger” Policy, But Still Prefers Licensing Deals

Merck appears to be distancing itself from a blanket "no merger" policy by offering a formula under which it would consider a large-scale transaction

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS045786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By